Cytopia begins Phase II

By Dylan Bushell-Embling
Thursday, 04 September, 2008

Cytopia [ASX: CYT] has commenced enrolment for its Phase 1b/II study of CYT997 for brain cancer.

CYT997 is a vascular disrupting agent being tested in patients with the aggressive brain cancer glioblastoma multiforme.

Around 30 patients will be involved in the study, which will be conducted at a number of clinical centres in Australia and overseas. CYT997 will be used in combination with two other marketed anticancer agents.

Glioblastomas often resurface even after surgical resection or radiation therapy, but are highly vascular and dependent on their own abnormal blood supply for growth. CYT997 is aimed at disrupting this supply.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd